Financial statements Notes to the consolidated financial statements continued 30.
Financial policies for risk management and their objectives continued Liquidity risk of assets liabilities Liquidity risk Less than one Two to five More than five year years years Total 2016 $m $m $m $m Cash and cash equivalents 155 155 Trade receivables 699 699 Interest-bearing loans and borrowings 73 787 860 Interest-bearing overdrafts 10 10 Interest-bearing Import and Export loans 64 64 Trade payables and accruals 329 329 378 787 409 Less than one Two to five More than five year years years Total 2015 $m $m $m $m Cash and cash equivalents 553 553 Trade receivables 432 432 Interest-bearing loans and borrowings 72 666 5 743 Interest-bearing overdrafts 12 12 Interest-bearing Import and Export loans 59 59 Trade payables and accruals 261 261 581 666 5 90 At 31 December 2016 the Group had undrawn facilities of $1,289 million 2015: $1,580 million.
Of these facilities, $1,093 million 2015: $1,381 million was committed and the remainder was uncommitted.
Derivative financial instruments Foreign exchange forward contracts The Group utilises currency derivatives to hedge significant future transactions and cash flows.
The Group uses foreign currency forward contracts in the management of its exchange rate exposures.
The instruments purchased are primarily denominated in the currencies of the Groups principal markets.
At the balance sheet date, the total notional amount of outstanding forward foreign exchange contracts that the Group was committed to have been translated at 31 December exchange rates as below: 2016 2015 $m $m Foreign exchange forward contracts JPY 6 Hikma Pharmaceuticals PLC 186 178 Hikma Pharmaceuticals plc
